Download - POCTRN Day 1 Klapperich
![Page 1: POCTRN Day 1 Klapperich](https://reader036.vdocuments.us/reader036/viewer/2022062600/58a3050a1a28ab90228c6456/html5/thumbnails/1.jpg)
PORTABLEMOLECULARDIAGNOSISOFHPV
CatherineKlapperich,Ph.D.Director,CenterforFuture
TechnologiesinCancerCareBostonUniversity
![Page 2: POCTRN Day 1 Klapperich](https://reader036.vdocuments.us/reader036/viewer/2022062600/58a3050a1a28ab90228c6456/html5/thumbnails/2.jpg)
CervicalCancerandHPV
Whendiagnosedearlyandaccurately,cervicalcancerhasahigh5yearsurvivalrate,emphasizingthevalueofearlydetection.
Cervicalcanceristhefourthmostcommoncancerinwomenworldwideandkills266,000womenperyear.
Approximately87%ofthesecasesareindevelopingcountries,wheretherearelimitedresourcesforscreening.
HPVisthecausativeagentinmostcervicalcancers.
![Page 3: POCTRN Day 1 Klapperich](https://reader036.vdocuments.us/reader036/viewer/2022062600/58a3050a1a28ab90228c6456/html5/thumbnails/3.jpg)
WHOGuidelinesforCervicalCancerScreening
What happens if there’s a positive test? Where does this fit in to the treatment chain?
![Page 4: POCTRN Day 1 Klapperich](https://reader036.vdocuments.us/reader036/viewer/2022062600/58a3050a1a28ab90228c6456/html5/thumbnails/4.jpg)
ComponentsofaPortableMolecularDiagnostic
Sample Collection
Isolate nucleic acids
Amplify Nucleic Acids
Readout
![Page 5: POCTRN Day 1 Klapperich](https://reader036.vdocuments.us/reader036/viewer/2022062600/58a3050a1a28ab90228c6456/html5/thumbnails/5.jpg)
Cao Q et al., PLoS ONE 7(3): e33176. (2012)
• 146 NPA and NPS samples were collected during 2008-2010 at Boston Medical Center (BMC) Beth Israel Deaconess Medical Center (BIDMC).
• Patients presenting with one or more of: fever, cough, sore throat, myalgia, nasal congestion, headache, malaise, or diarrhea.
• 12 months to 70 years.
• RT-PCR Chip for INFLA
![Page 6: POCTRN Day 1 Klapperich](https://reader036.vdocuments.us/reader036/viewer/2022062600/58a3050a1a28ab90228c6456/html5/thumbnails/6.jpg)
![Page 7: POCTRN Day 1 Klapperich](https://reader036.vdocuments.us/reader036/viewer/2022062600/58a3050a1a28ab90228c6456/html5/thumbnails/7.jpg)
DesignforPOC– DesignforMinimalInstrumentation
• Size
• Shelflife
•Passiveflow
•Heatwithminimal/no
instrumentation
• Intuitivereadoutwithoutinstrumentation
Goal:Getamoleculartesttoaremoteclinic.
![Page 8: POCTRN Day 1 Klapperich](https://reader036.vdocuments.us/reader036/viewer/2022062600/58a3050a1a28ab90228c6456/html5/thumbnails/8.jpg)
NucleicAcidIsolation
Rodriguezetal.,Anal.Chem.,2015,87 (15),pp7872–7879
![Page 9: POCTRN Day 1 Klapperich](https://reader036.vdocuments.us/reader036/viewer/2022062600/58a3050a1a28ab90228c6456/html5/thumbnails/9.jpg)
ValidationofAmplifiableNAAnalysisofLAMPinDifferentPapers
Linnes JC, Rodriguez NM, Liu L, Klapperich CM, Biomed Microdevices. 2016 Apr;18(2):30.
![Page 10: POCTRN Day 1 Klapperich](https://reader036.vdocuments.us/reader036/viewer/2022062600/58a3050a1a28ab90228c6456/html5/thumbnails/10.jpg)
NucleicAcidAmplification
Isothermal Techniques LAMPHDA
![Page 11: POCTRN Day 1 Klapperich](https://reader036.vdocuments.us/reader036/viewer/2022062600/58a3050a1a28ab90228c6456/html5/thumbnails/11.jpg)
DNAExtractedfromStool,AmplifiedwithoutInstrumentation
HuangS,etal.(2013),PLoSONE8(3):e60059.
60-65°C
![Page 12: POCTRN Day 1 Klapperich](https://reader036.vdocuments.us/reader036/viewer/2022062600/58a3050a1a28ab90228c6456/html5/thumbnails/12.jpg)
Linnes,etal.,RSCAdv.2014Jan1;4(80):42245-42251.
Lysis,IsolationandAmplificationonPaperChlamydiaCells(DNA)
![Page 13: POCTRN Day 1 Klapperich](https://reader036.vdocuments.us/reader036/viewer/2022062600/58a3050a1a28ab90228c6456/html5/thumbnails/13.jpg)
Readout
![Page 14: POCTRN Day 1 Klapperich](https://reader036.vdocuments.us/reader036/viewer/2022062600/58a3050a1a28ab90228c6456/html5/thumbnails/14.jpg)
ClinicalInfluenzaASamples:IsothermalAmplificationandPaperReadout
Rodriguezetal.,Anal.Chem.,2015,87 (15),pp7872–7879
![Page 15: POCTRN Day 1 Klapperich](https://reader036.vdocuments.us/reader036/viewer/2022062600/58a3050a1a28ab90228c6456/html5/thumbnails/15.jpg)
IntegrationforHPV16DetectioninCervicalSwabSamples
![Page 16: POCTRN Day 1 Klapperich](https://reader036.vdocuments.us/reader036/viewer/2022062600/58a3050a1a28ab90228c6456/html5/thumbnails/16.jpg)
RunningtheChip
N.M.Rodriguez,etal.LabChip,2016,16,753-763
![Page 17: POCTRN Day 1 Klapperich](https://reader036.vdocuments.us/reader036/viewer/2022062600/58a3050a1a28ab90228c6456/html5/thumbnails/17.jpg)
Results
N.M.Rodriguez,etal.LabChip,2016,16,753-763
![Page 18: POCTRN Day 1 Klapperich](https://reader036.vdocuments.us/reader036/viewer/2022062600/58a3050a1a28ab90228c6456/html5/thumbnails/18.jpg)
MultiplexingHPV16andHPV18
![Page 19: POCTRN Day 1 Klapperich](https://reader036.vdocuments.us/reader036/viewer/2022062600/58a3050a1a28ab90228c6456/html5/thumbnails/19.jpg)
JaneDx,Inc.IncubatingattheBUPhotonicsCenter
Rajan Dewar, M.D. Catherine Klapperich, Ph.D. Mario Cabodi, Ph.D. Natalia Rodriguez, Ph.D.
![Page 20: POCTRN Day 1 Klapperich](https://reader036.vdocuments.us/reader036/viewer/2022062600/58a3050a1a28ab90228c6456/html5/thumbnails/20.jpg)
Customer&ValueChain• TargetCustomersandValueChainDynamics:
• USpathlabs/Consumerplay• GeneralstrategyforLMIC:
• Ministryofhealth• NGOs• Providers• Patients
• Firsttargetmarket: India• Privatepracticesanddistributorswillbuyfromusandselldirectlytopatients.• Wewillthustargetdistributors,privatepractice providers,thenstategovernment• distributors(price,performance)à users(price)
![Page 21: POCTRN Day 1 Klapperich](https://reader036.vdocuments.us/reader036/viewer/2022062600/58a3050a1a28ab90228c6456/html5/thumbnails/21.jpg)
RevenueModel&PotentialMarketSize:• Reimbursement: LMICmarketsarehighlysegmented:
• Insurance/reimbursementstructurenearlynon-existent(country-dependent)
• WillpatientspayOut-of-pocketfortests?• India:growingmiddleclasspays100%oopfortestsalready• Verysensitive toprice
• RevenuePotential:India• Customerswouldpay$10distributorspertest(assuming100%markup);distributorsbuyfromJaneDXat$5pertest.
• Screeningguideline:Womenages35– 64,cytologyevery3years;344millionwomenareeligible forscreening
• Test110millionwomeneveryyearà $550M/yearpotentialrevenue
21
![Page 22: POCTRN Day 1 Klapperich](https://reader036.vdocuments.us/reader036/viewer/2022062600/58a3050a1a28ab90228c6456/html5/thumbnails/22.jpg)
FeasibilityStudyLate2016
SriRamachandra
MedicalCollege
(MOU)
TamilNadu
JaneDx,Inc.
Boston,MA
1000patients,3monthPilot.IntegratedintoCurrentScreeningProgram.
![Page 23: POCTRN Day 1 Klapperich](https://reader036.vdocuments.us/reader036/viewer/2022062600/58a3050a1a28ab90228c6456/html5/thumbnails/23.jpg)
TamilNadu– PilotProgram
Totalnumberoftargetwomenscreened:2,91,525+1,96,559$1.5perpatient
MorewomendiefromcervicalcancereveryyearinIndia thananywhereelseintheworld,accordingtotheCervicalCancer-FreeCoalition
JaneDx
![Page 24: POCTRN Day 1 Klapperich](https://reader036.vdocuments.us/reader036/viewer/2022062600/58a3050a1a28ab90228c6456/html5/thumbnails/24.jpg)
POCTRNResourcesLeveraged
• CFTCCAlphaPrototypingCoretoMakeEarlyChipsforProofofConcept.
• CIMITPrimaryCareCenterPilotGrant• CIMITCRAASHCourseandMentorship• CFTCCClinicalNeedsAssessmentCoreforIndiaMarketResearch/ContactEstablishment.
• JHUSTICenterDiscussions/Mentorship/TrainingRe:SamplePreparationofCervicalSwabs.
![Page 25: POCTRN Day 1 Klapperich](https://reader036.vdocuments.us/reader036/viewer/2022062600/58a3050a1a28ab90228c6456/html5/thumbnails/25.jpg)
Acknowledgements Current Lab Members Dr. Andy FanDr. Sharon WongNatalia RodriguezWinnie WongLena LiuConstantinos KetavatisGeorge PrattProf. Mario Cabodi
AlumniDr. Jacqueline LinnesDr. Jason KellerDr. Cassandra NoackSamantha ByrnesDr. Jaephil DoMichelle Wong Dr. Mincheol Kim Dr. Shichu Huang Nga HoDr. Qingqing CaoDr. Sonali MahalanabisDr. Jane ZhangDr. Arpita BhattacharyyaJared SaffieJake TruebMelike Karakaya
NIH U54 EB015403NIH R01 EB008268NIH R44 AI073221NIH R21 AI071261NIH R41 AI092913
www.bu.edu/cftccwww.bu.edu/klapperich